Market News AIOpen the app

BHVN stock news · Biohaven Ltd.

Stories about Biohaven Ltd. (BHVN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for BHVN

Follow Biohaven Ltd. (BHVN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BHVN
Free on the App Store and Google Play, or on the web.
  1. Oct 30, 2026, 9:56 AM ET · Opinion

    Deutsche Bank cut its price target for Biohaven to $23 from $26 but still recommends buying the stock.

    Neutral

    Deutsche Bank lowered its Biohaven share target to $23 from $26 but kept its Buy rating. The mixed view does not change the company's outlook.

  2. Oct 29, 2026, 7:17 PM ET · Market

    Biohaven shares its financial results for the third quarter of 2026 and news about drug approvals.

    Neutral

    Biohaven's quarterly loss was smaller than expected, and the FDA accepted its resubmitted drug application. A study pause over rodent findings tempers those steps, leaving the report mixed.

  3. Oct 22, 2026, 8:21 AM ET · Market

    12 health care stocks are changing a lot before the market opens on Thursday.

    Neutral

    Biohaven shares rose about 39% before trading, but the article gives no company news behind the move. It does not change the outlook for the business.

  4. Oct 22, 2026, 7:35 AM ET · Trial

    Biohaven Ltd. says the FDA accepted its new drug application for Vyglxia to treat spinocerebellar ataxia.

    Good for BHVN

    Biohaven's drug application for spinocerebellar ataxia has returned to FDA review after new supportive analyses. This favors the company, but approval is still uncertain.

  5. Oct 15, 2026, 5:36 PM ET · Market

    Biohaven Ltd. has teamed up with Ono Pharmaceutical in a big agreement.

    Good for BHVN

    Biohaven licensed its IgG degrader medicines to Ono in parts of Asia. The promised initial payment, possible milestone payment, and sales royalties make this favorable for Biohaven.

  6. Sep 18, 2026, 8:06 AM ET · Market

    Xenon Pharmaceuticals, Steel Dynamics, Nucor, and other major stocks dropped in early trading on Friday.

    Neutral

    Biohaven fell 6.4% to $13.00 in pre-market trading after jumping the prior day; the piece reports only price action and no new company information, so the reading unchanged.

  7. Aug 7, 2026, 4:19 PM ET · New boss

    Biohaven Ltd. (BHVN) details leadership transitions, including the exit and election of directors and the appointment of new officers along with their compensation arrangements.

    Neutral

    Biohaven Ltd. has filed a Form 8-K detailing significant changes in its leadership, including the departure and appointment of directors and officers. Such changes can lead to uncertainty regarding the company's future direction and operational effectiveness, making it a critical update for investors.